These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25423889)

  • 1. Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the Child-Pugh score classification system.
    Dyk P; Weiner A; Badiyan S; Myerson R; Parikh P; Olsen J
    Pract Radiat Oncol; 2015; 5(3):176-182. PubMed ID: 25423889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
    Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
    Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
    Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
    Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
    Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
    Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
    Sanuki N; Takeda A; Oku Y; Mizuno T; Aoki Y; Eriguchi T; Iwabuchi S; Kunieda E
    Acta Oncol; 2014 Mar; 53(3):399-404. PubMed ID: 23962244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases.
    Howells CC; Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD; Miften M
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e441-6. PubMed ID: 22682809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
    Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Son SH; Choi BO; Ryu MR; Kang YN; Jang JS; Bae SH; Yoon SK; Choi IB; Kang KM; Jang HS
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1073-80. PubMed ID: 20207492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
    Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
    Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
    Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
    Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
    Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
    Rusthoven KE; Kavanagh BD; Cardenes H; Stieber VW; Burri SH; Feigenberg SJ; Chidel MA; Pugh TJ; Franklin W; Kane M; Gaspar LE; Schefter TE
    J Clin Oncol; 2009 Apr; 27(10):1572-8. PubMed ID: 19255321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
    Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.
    Nakamura Y; Kimura T; Higaki T; Honda Y; Komoto D; Yamagami T; Iida M; Nagata Y; Honda Y; Aikata H; Chayama K; Awai K
    Jpn J Radiol; 2015 Oct; 33(10):627-35. PubMed ID: 26227061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
    Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
    Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.